Mariner LLC Has $1.58 Million Position in Smith & Nephew plc (NYSE:SNN)

Mariner LLC raised its holdings in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 53.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,146 shares of the medical equipment provider's stock after buying an additional 22,218 shares during the period. Mariner LLC's holdings in Smith & Nephew were worth $1,577,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC purchased a new position in shares of Smith & Nephew in the fourth quarter worth about $431,000. Townsquare Capital LLC increased its position in shares of Smith & Nephew by 19.0% during the fourth quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock worth $432,000 after purchasing an additional 2,798 shares in the last quarter. Sterling Capital Management LLC acquired a new stake in shares of Smith & Nephew in the fourth quarter valued at about $265,000. Raymond James Financial Inc. purchased a new position in Smith & Nephew in the 4th quarter worth approximately $4,992,000. Finally, Quadrant Capital Group LLC boosted its stake in Smith & Nephew by 37.4% during the fourth quarter. Quadrant Capital Group LLC now owns 7,431 shares of the medical equipment provider's stock worth $183,000 after buying an additional 2,024 shares during the last quarter. Institutional investors own 25.64% of the company's stock.

Smith & Nephew Stock Down 1.3 %

Smith & Nephew stock traded down $0.35 during midday trading on Friday, hitting $26.65. The stock had a trading volume of 928,869 shares, compared to its average volume of 823,199. The stock has a market cap of $11.67 billion, a P/E ratio of 12.34, a P/E/G ratio of 1.26 and a beta of 0.71. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The business has a fifty day moving average price of $27.52 and a 200 day moving average price of $26.34. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63.

Smith & Nephew Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be issued a $0.447 dividend. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.29. The ex-dividend date of this dividend is Friday, March 28th. This represents a dividend yield of 2.5%. Smith & Nephew's dividend payout ratio (DPR) is 41.20%.

Wall Street Analysts Forecast Growth

SNN has been the subject of several research reports. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $27.00 target price on shares of Smith & Nephew in a research report on Monday, March 17th. UBS Group downgraded Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. HSBC lowered Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday. Finally, StockNews.com upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $27.00.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.